ArticlePloS one2026
Differential modulation of haematopoietic and oxidative injury by PARP-1 and ATR kinase inhibition in a murine model of acute irradiation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporal Modulation of Acute Radiation Injury by Post-Exposure PARP-1 versus ATR Kinase Inhibition.
backgroundPARP-1 and ATR inhibitors have been employed as radiosensitizers in cancer therapy. In addition to this, there is little evidence about the role of these chemicals after a dose of radiation, specifically in relation to reducing damage to healthy cells rather than increasing it.
objectiveThe goal of this study was to determine if PARP-1 or ATR kinase inhibitors, when delayed administered, could decrease the severity of the condition caused by an acute dose of radiation and compare the impact of PARP-1 and ATR inhibitors.
methodsMice of the C57BL/6 strain were subjected to a total body irradiation dose of 2.5 Gy γ-rays. In each experiment, thirty minutes following exposure to IR, either the PARP inhibitor, olaparib at 50 mg/kg or the ATR kinase inhibitor VE-821 at 25 mg/kg was injected intraperitoneally into the mice. The parameters of blood were measured at the same time as oxidative stress, including the activity of superoxide dismutase and levels of malondialdehyde. Examination of DNA damage and repair dynamics was done through the use of γ-H2AX immunofluorescence.
resultsFollowing exposure to ionising radiation, mice which had received a PARP inhibitor showed less marked haemoglobin reduction and less radiation-induced leucopenia than control mice exposed to radiation alone. The modifications were accompanied by a decrease in lipid peroxidation plus enhanced antioxidant activity. This observation that PARP inhibition enhances repair of DNA double-strand breaks is consistent with earlier data from other researchers. In contrast the protective effects of the ATR kinase inhibitor were not apparent when administered after the DNA damage had been inflicted in any of the parameters examined.
conclusionWhile administering PARP inhibitors following the exposure to ionising radiation was found to reduce the severity of the condition experienced by the subject, as a result of acute radiation syndrome, the same was not seen when the treatment with ATR inhibitors was given to affected subjects. The results of this study show the significance of administering therapeutic agents at the right time to stop the injury to normal cells when DNA repair pathways are activated by exposure to ionising radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.